Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]
- 1 June 1995
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 39 (6), 700-703
- https://doi.org/10.1111/j.1365-2125.1995.tb05732.x
Abstract
Twenty-six healthy males took part in this double-blind, randomised, placebo-controlled, two-period, cross-over study. Pantoprazole (40 mg) (test) or placebo (reference) were administered once daily, for 8 days, with a 3 week washout period. A single oral dose of 25 mg warfarin sodium was co-administered with pantoprazole or placebo on Day 2 of each treatment period. The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0.168 h) of prothrombin time and AUC(0.168 h) of factor VII, and of Cmax, AUC and t1/2 of both R- and S-warfarin fell within the equivalence range of 80% to 125%. These results suggest that pantoprazole does not alter the pharmacokinetics or pharmacodynamics of warfarin.Keywords
This publication has 13 references indexed in Scilit:
- The interaction of proton pump inhibitors with cytochromes P450.Alimentary Pharmacology & Therapeutics, 1994
- Dose-range finding study with the proton pump inhibitor pantoprazole in acute duodenal ulcer patients.1992
- Model to Detect Warfarin-Drug Interactions in ManClinical Drug Investigation, 1992
- Presentation of results from bioequivalence studies.1992
- Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.1991
- Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.1991
- Lack of pharmacokinetic interaction as an equivalence problem.1991
- Good Clinical Practice for Trials on Medicinal Products in the European Community: CPMP Working Party on Efficacy of Medicinal ProductsBasic & Clinical Pharmacology & Toxicology, 1990
- Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.1990
- Single intravenous administration of the H+, K+‐ATPase inhibitor BY 1023/SK&F 96022—inhibition of pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in manAlimentary Pharmacology & Therapeutics, 1990